Dexcom (DXCM) Q4 2025 earnings summary

Executive summary

• Q4 2025 revenue reached $1.26 billion, up 13% year-over-year, driven by strong new customer demand and the successful G7 15-Day product launch.

• CEO outlined strategic priorities: premier glucose sensing, customer experience excellence, and international market expansion.

• Significant operational improvements in manufacturing and logistics led to higher inventory and improved gross margin.

• FDA clearance received for Smart Basal insulin optimizer and new patch technology, with early access launch in Q1 2026.

• Stelo contributed $130 million in 2025 revenue, with new app features planned for 2026.

Financial highlights

• Q4 2025 worldwide revenue was $1.26 billion, up from $1.11 billion in Q4 2024 (13% growth reported, 12% organic).

• U.S. revenue grew 11% to $892 million; international revenue rose 18% to $368 million, with France as a standout market.

• Q4 non-GAAP gross profit was $799.8 million (63.5% margin), up from 59.4% in Q4 2024.

• Operating income was $331.5 million (26.3% margin), up from $209.5 million (18.8%) in Q4 2024.

• Adjusted EBITDA reached $422.2 million (33.5% margin), up from $300.1 million (27.0%) in Q4 2024.

• Q4 GAAP net income was $267.3 million ($0.68 per diluted share), up from $151.7 million ($0.38) in Q4 2024.

• Free cash flow surpassed $1 billion for the first time in 2025.

Outlook and guidance

• 2026 revenue guidance: $5.16–$5.25 billion, representing 11–13% growth, assuming stable coverage and incremental contributions from Stelo and new products.

• Full-year 2026 non-GAAP gross margin expected at 63–64%, operating margin at 22–23%, and adjusted EBITDA margin at 30–31%.

• Margin expansion of 200–300 bps anticipated, driven by lower freight costs, manufacturing efficiencies, and G7 15-Day contribution.

• Investments planned for sales, innovation, and Ireland manufacturing facility launch in late 2026.

• Guidance assumes no major changes in coverage; Medicare expansion for Type 2 non-insulin users could be a significant upside.